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Summary Seventy three children with rhabdomyosarcoma were treated by members of the Children's Solid
Tumour Group during the period, 1974-1981. The extent of disease at diagnosis was found to be the major
influence affecting outcome. Children with tumours confined to the tissue of origin with no evidence of nodal
or metastatic spread, had a predicted actuarial 5-year survival rate of 86%. However children with
'unconfined' tumours, i.e. those with extension of disease outside the tissue of origin, had a much poorer
prognosis with an actuarial 5-year survival rate of only 21%. Two other factors, histological type and site of
primary tumour, appeared to affect prognosis but were not independent of the extent ofdisease at diagnosis.
All children were treated according to protocol. Fifty-two patients showed a complete response to initial
therapy and 4 of the 11 partial responders achieved a full remission after additional therapy. The overall
complete response rate was therefore 77%. Nineteen children who achieved a complete response on initial
treatment subsequently relapsed. Only 3 of these children were alive with no evidence of disease 3 years later,
a salvage rate of 15%. "Late" relapses, defined as those occurring more than 2 years after diagnosis, were
seen in only 5 children, 4 in boys with primary paratesticular tumours.
The protean manifestations of rhabdomyosarcoma
in childhood render it a-fascinating and challenging
tumour to diagnose and treat. Rhabdomyosarcoma
constitutes about 4% of all the malignant tumours
seen in childhood and in England, Scotland and
Wales, approximately 50 new cases occur annually
in children under the age of 15 years (Draper et al.,
1982). The primary tumour develops in many sites
but most frequently in the head and neck region,
urogenital tract, trunk and extremities. Rhabdomyo-
sarcoma is a highly malignant tumour with a
tendency to infiltrate adjacent structures and to
metastasise to lungs, bone, lymph nodes and
sometimes to bone marrow.
During the 1960's treatment with surgery and
radiotherapy, either alone or in, combination,
produced 5-year survival rates of 14-35% (Ehrlich
et al., 1971; Kilman et al., 1973; Maurer et al.,
1977; Sutow et al., 1970). The introduction of
multiple agent chemotherapy into treatment
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protocols during the early 1970's resulted in a
considerable improvement in prognosis. Using the
multimodality approach to treatment of rhab-
domyosarcoma, disease-free survival rates of 90%
at 3 years have been reported for patients
presenting with non-metastatic disease in sites such
as the orbit and genito-urinary tract. (Hays et al.,
1981; Sutow et al., 1982).
In January 1974 the Children's Solid Tumour
Group (CSTG) was set up between St.
Bartholomew's and the Royal Marsden Hospitals,
with the objectives of improving the understanding
of the biology of the solid tumours of childhood
and of developing more effective treatment
protocols.
Patients and methods
This report describes the experience of the CSTG
for the period February 1974 to December 1981,
during which time 73 children with rhabdomyo-
sarcoma were treated by members of the group.
The analysis of survival and relapse rates includes
events occurring up to the end of December 1982.
Pathology
In all cases the diagnosis was confirmed by
histological examination of the tumour tissue.
Routine stains of the histological sections included
haematoxylin and eosin, periodic acid schiff and
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phosphotungstic acid haematoxylin. Since 1977,
tumour tissue has been examined by electron micro-
scopy whenever possible. Fifty nine patients had their
initial biopsy or surgery carried out at the referring
hospital and the pathological material of all these
cases was reviewed by a senior consultant
pathologist at one of the two collaborating
hospitals. Nineteen (32%) of these 59 cases had
been referred with a different diagnosis, which was
revised to rhabdomyosarcoma following review of
the histology. This finding emphasises the need for
these relatively uncommon tumours to be examined
by a pathologist with considerable experience in the
field of paediatric oncology.
The histological subtypes included in this study
are those classified as embryonal sarcoma and the
embryonal, alveolar and botryoid types of rhab-
domyosarcoma. Two cases where the type of rhab-
domyosarcoma could not be determined are also
included. No cases of pleomorphic rhabdomyo-
sarcoma have been seen.
Staging
One of the objectives of the study was to relate the
extent of the disease at diagnosis to outcome. Three
different staging systems were used in an attempt to
determine a classification which would give a good
differential with regard to outcome. The three
staging systems which have been used are as
follows:
1. St. Jude (Pratt et al., 1972)
2. T.N.M. (UICC, 1982)
3. Barts/Marsden
All 3 systems refer to the pre-treatment clinical
assessment of the disease state and are outlined in
Tables I-III.
Staging investigations
After histological confirmation of the diagnosis, the
investigations done as part of the initial staging
assessment on all patients included full blood
count, chest X-ray, bone scan, bone marrow
aspirate and trephine. Other investigations such as
abdominal ultrasound, C.T. scanning, i.v.
urography, lymphangiography and lumbar puncture
were done when appropriate.
Definition and evaluation ofresponse
(1) Complete response (CR):
disappearance of all evidence of disease for more
than one month
(2) Good partial response (GPR):
>50% reduction in size of tumour at the
primary site and clearance of metastatic disease
for more than one month
(3) Poor partial response (PPR):
<50% reduction in size of tumour at the
primary site but clearance of all metastatic
disease for more than one month
(4) No response (NR):
persistence or progression of disease.
Table I St. Jude staging system
Stage Description
I Localised disease
-completely resectable
II Regional disease
A -completely resectable
B -nonresectable or partially resectable
III Generalised disease
A-distant metastases with normal bone marrow
B -distant metastases with positive bone marrow
Table II TNM Staging system
T N M
Primary tumour Regional lymph nodes Distant metastases
T1 Tumour confined No No evidence of regional MO No evidence of
to the organ or lymph node involvement distant metastases
tissue oforigin
Tia Tumour 5cm. or N1 evidence of regional M1 evidence of
less lymph node involve- distant metastases
ment
Tib Tumour more than
5cm
T2 Tumour involving
contiguous organs
or tissues or with
adjacent malignant
effusion.CHILDHOOD RHABDOMYOSARCOMA 197
Table III Barts/Marsden staging system
Stage Description
I Localised disease confined to tissue of
origin
A-completely resected
B -not resected
II Regional disease
A-extending outside tissue oforigin
to involve contiguous bone or nerve
B-with nodal metastases
III Generalised disease
A-without marrow involvement
B-with marrow involvement
The nature of the investigation chosen to evaluate
response depended on the site and stage of the
disease. Methods of evaluation, have included
clinical examination, ultrasound and C.T. scanning,
bone marrow trephine, lumbar puncture and repeat
biopsy at the primary site. Reappearance or
progression of the disease after a partial or
complete response has been defined as a relapse.
Treatment protocols
Between February 1974 and January 1977 the
allocation of patients to a treatment protocol was
determined by the stage of the disease, based on the
St. Jude staging system. All children received
intensive chemotherapy with vincristine,
actinomycin-D and cyclophosphamide for one year
and in addition children with non-metastatic disease
were given radical radiotherapy, (40-60Gy) to the
site of the primary tumour. This treatment regimen
is outlined in Table IV.
From February 1977 onwards, treatment was
intensified by the addition of adriamycin for "poor
risk" cases, i.e. children with Stage IIB tumours in
parameningeal sites and all Stage III cases.
Children at the Royal Marsden Hospital with rhab-
domyosarcoma of the orbit were also treated with
adriamycin but on a slightly modified regimen.
These revised protocols are outlined in Table V.
Statistical analysis
Standard Kaplan Meier methods have been used
for calculating and projecting curves of overall
survival and periods of disease-free survival. Tests
of statistical differences between curves have been
analysed using a standard log rank test.
Results
A total of 73 children with rhabdomyosarcoma and
embryonal sarcoma have been treated during the
period February 1974-December 1981. Early results
of treatment of 11 of these children have been
reported previously (Malpas et al., 1976).
Primary site
The distribution of tumours by primary site is
shown in Table VI. The commonest site of disease
in our series was the orbit, accounting for 21% of
the total. The relatively high number of children
with orbital lesions may reflect local referral
patterns resulting from the close association of the
two collaborating hospitals with the country's
major specialist eye hospital. It is estimated that
40-50% of all cases of orbital rhabdomyosarcoma
in England and Wales are treated by members of
the CSTG.
Table IV Treatment protocol (Feb. 1974-Jan. 1977)
Stage (St. Jude) Surgery Radiotherapy Chemotherapy
I Complete excision 4000-6000cGy VAC*
with resection of over 6-7 weeks
II A adjacent lymph
nodes in Stage IIA
II B Partial excision or 4000-6000cGy VAC
biopsy with deter- over 6-7 weeks
mination of extent
of tumour
III A Biopsy only Palliative RT VAC
B to bulky disease
*VAC-Vincristine 1.5mgm-2i.v.
Actinomycin D 0.6mgm-2i.v.
Cyclophosphamide 300mgm-2i.v.
Courses of chemotherapy given weekly x 6 concurrently with radiotherapy and
then fortnightly for one year.198 J.E. KINGSTON et al.
Table V Treatment protocol (Feb. 1977-Dec. 1981)
Stage (St. Jude) Surgery Radiotherapy Chemotherapy
Good risk
I Complete excision 4000-6000cGy (a) 2 courses of
IIA with resection of to site of VAC* prior
IIB-other adjacent lymph primary tumour to RT
than para- nodes in Stage IIA (b) starting 2
meningeal Biopsy only in weeks after RT-
sites Stage IIB VAC at 3 week
intervals to 1
year
Orbital tumours Biopsy ,, (a) 2 courses of
(RMH) VAC prior to
RT
(b) VCt during RT
(c) VAC, VAC, VA¶
given at 3 week
intervals for 9
cycles post RT
Poor risk
IIB-para- Biopsy 4000-6000cGy to (a) 2 courses of
meningeal residual tumour CVA** prior
sites after chemotherapy to RT
and to sites where (b) VC during RT
III A+B tumour existed (c) starting 2 weeks
prior to chemo- after RT CVA
therapy 2 weekly x 8
followed by
VAC at 2 week
intervals for
1 year.
*VAC See Table IV.
**CVA Vincristine
Cyclophosphamide
Adriamycin
tVC Vincristine
Cyclophosphamide
¶VA Vincristine
Adriamycn
1.5mgm-2i.v.
400mgm-2i.v.
4Omgm-2i.v.
1.5mgm-2i.v.
200mgm-2i.v.
-2' 1.5mgm i.v.
40mgm-2i.v.
The relatively small number of very young boys
with pelvic primary tumours included in this study
is because these patients are usually referred to the
Consultant Paediatric Urologist at the Hospital for
Sick Children, Great Ormond Street.
Histological type
The distribution of cases by histological type is
shown in Table VII. The embryonal/botryoid
classification accounted for 76% of the cases. The
alveolar type (22%) was seen predominantly in
limb, pelvic and perineal sites. This predominance
of alveolar histology in extremity lesions was also
reported by the Intergroup rhabdomyosarcoma
study IRS-1, (Hays et al., 1982a).
Age distribution
The frequency of rhabdomyosarcoma by age is
shown in Figure 1. Seventy three per cent of
patients were aged <10 years at diagnosis. The
median age was 6 years 2 months with a range of 2
weeks to 15 years 11 months.
Stage
Classification of patients by the three staging
systems is shown in Table VIII. Twenty children
(28%) had tumours which were confined to the
tissue of origin and completely resected
(Barts/Marsden (BM) Stage IA), while a further 20
children had locally confined disease which wasCHILDHOOD RHABDOMYOSARCOMA 199
Table VI Distribution ofpatients by site
Site
Orbit
Other head and neck
Parameningeal sites-
-nasopharynx
-para nasal sinus
Face
Neck/Larynx
Paratesticular
Vagina
Other pelvic/retroperitoneal sites
Pelvis
Perineal
Prostate
Retroperitoneum
Extremity
Lower limb
Upper limb
Trunk/Limb girdle
Intrathoracic
C.N.S.
Primary site not identified
No. ofpatients
16
9
(3)
(1)
(3)
(2)
(9)
(3)
(1)
(2)
(3)
(1)
11
6
15
0.
4.0
cx
E
z
4
5
3
2
2
Total 73
10
8
6
4
2
0
Alveolar
histology
Embryonal
LJhistology
0 2 4 6 8 10 12 14
Age (y)
Figure 1 Distribution of patients by age at diagnosis.
Shaded areas represent children with alveolar
histology.
Table VII Distribution ofpatients by histological type
Tumour histology No. ofpatients % oftotal
Embryonal/botryoid 38 52
Embryonal sarcoma 17 24
Alveolar 16 22
Rhabdomyosarcoma (n.o.s.) 2 2
Table VIII Distribution ofpatients by stage
Barts/Marsden TNM St. Jude
No. No. No.
Stage patients Stage patients Stage patients
IA 20 T10NoM0 28 I 17
IB 20 TiaNiMo 3 IIA 3
IIA 9 TlbNOMO 11 IIB 39
IIB 10 TlbNl MO 4 IIIA 7
IIIA 7 TlbNOMl 5 IIIB 7
IIIB 7 TlbNlMl 4
T2NoMo 9
T2N1MO 4
T2NoM, 5
either partially resected or merely biopsied (BM
Stage IB). In 9 children without nodal or metastatic
disease, the tumour extended outside the tissue of
origin to involve contiguous bone (BM Stage IIA).
Ten children had lymph node involvement but no
other evidence of systemic spread (BM Stage IIB).
Four of these children however had evidence of
local infiltration. The remaining 14 children had
metastatic disease which, in 7, involved the bone
marrow.
When patients are staged according to the St.
Jude system, there is a rather uneven distribution of
cases between the five stages, with a large
proportion (52%) falling into Stage IIB.
Lymphatic spread was not seen in any of the 16
children with orbital tumours, but was common in
other head and neck sites (4/9). No lymphatic
involvement was observed in any of the children
with lesions of the trunk. The relative infrequency
of lymphatic spread in patients with orbital and
truncal lesions has also been noted by the Inter
Group Rhabdomyosarcoma Study (Donaldson et
al., 1973; Lawrence et al., 1977).
Survival analysis
The median duration of follow up for this group of
patients is 49 months with a range of 14-103
months. The predicted actuarial 5-year survival rate
for all patients is 58% with a disease-free survival
rate of 45% (Figure 2). No relapse or death has
been observed more than 4 years after diagnosis.
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0 n 0 1 1 OLMMMMJ200 J.E. KINGSTON et al.
.1
SQ
.-b .I
I
~1.
U
o..
1
0) 2 3 : 6" 7
J erall survival
R .fres survival
S 9
Figure 2 Actuarial survival curves for children with rhabdomyosarcoma treated at St. Bartholomew's and
The Royal Marsden Hospitals between January 1974 and December 1981.
Effect ofstage
The survival curves for patients staged according to
the St. Jude system are shown in Figure 3. For
Stage I patients the actuarial 5-year survival rate is
73%, compared to 65% for all Stage II patients.
The difference between these survival rates is not
significant (P=0.39). It would therefore appear that
the St. Jude staging system does not give a good
differential with regard to outcome between Stage I
and II patients.
Survival curves for patients staged according to
the TNM system are shown in Figure 4. These
show that the patients with the best prognosis are
those with tumours classified as T1 No MO for
whom the actuarial survival rate at 5 years is 85%.
However patients with T2 No MO tumours, i.e.
those with tumours extending outside the tissue of
origin, but without nodal or metastatic disease,
fared badly, with a survival rate of only 25%.
Similarly, patients with nodal involvement but no
evidence of metastatic spread, T1+ 2 N1 Mo did
badly with a predicted 5-year survival rate of 30%.
However, excluding the children with T2 tumours
in this group, patients with nodal spread but locally
confined tumours T1 N1 Mo had an intermediate
prognosis with a 48% survival rate at 5 years.
Survival curves for patients staged according to
the Barts/Marsden system are shown in Figure 5.
There is a predicted actuarial 5-year survival rate of
86% for all Stage I patients, 78% and 95% for
Stage IA and IB respectively. This difference is not
significant (P=0.25) It therefore appears that
surgical resection of locally-confined tumours does
not make a significant difference to overall survival.
This finding is of particular relevance for patients
with orbital rhabdomyosarcoma for whom total
excision of the tumour with enucleation used to be
the treatment of choice. The poor survival rate of
the Barts/Marsden Stage II patients (26%), with
rates of 22% and 40% for BM Stages IIA and IIB
respectively, means that both local extension of the
tumour outside the tissue of origin and nodal
spread are bad prognostic features.
In all three staging systems patients with
metastatic disease do badly, with a survival rate of
< 15% at 2 years. Of the 14 patients with
generalised disease at presentation only one child is
alive and disease free at 3 years from diagnosis.
Effect ofsite
The best survival rates were seen in children with
tumours of the orbit, the majority of whom had
disease confined within the orbit. These children
had a predicted 5-year survival rate of 94%.
Children with tumours in other head and neck
sites did less well with a survival rate of 50%. Boys
with paratesticular tumours and girls with vaginal
tumours also tended to have a good prognosis with
5-year survival rates of 81% and 67% respectively.
Children with tumours in other pelvic sites did
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Figure 3 Overall survival of children with rhabdomyosarcoma staged according to the St. Jude staging
system.
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particularly badly, with a predicted survival rate of
only 31% at 5 years. Children with limb and trunk
primaries had an intermediate prognosis, 44% at 5
years (Figure 6).
Effect ofage
Age did not appear to have any significant effect
on prognosis, and we did not find that infants have
a worse prognosis than older children (Grosfield et
al., 1969). Of the 5 children diagnosed under the
age of one year, all are currently alive and disease-
free, with a median follow up of 77 months (range
57-91). Three of these 5 infants were girls with
vaginal botryoid tumours.
Effect ofsex
Forty eight per cent of the female children have
died compared to only 23% of the male patients,
with survival rates of 69% and 44% for males and
females respectively. The poorer survival rates for
females may, in part, be explained by the higher
incidence in this series of girls with pelvic tumours
and with tumours in head and neck sites. The
difference in survival between the sexes just fails to
reach statistical significance (P=0.067), (Figure 7).
Effect ofhistology
Children with tumours classified as embryonal
rhabdomyosarcoma or embryonal sarcoma had a
better prognosis than those with tumours of
II
n,- .a.
I
3.
alveolar histology; 66% survival at 5 years for
those with embryonal histologies, compared to only
25% for those with alveolar histologies
(P<0.001), (Figure 8).
Response to treatment
Eleven children required significant modifications
to planned treatment because of drug toxicity or
profound bone marrow suppression. Exclusion of a
drug, reduction of drug dose by more than 33% of
the planned dose, or a delay of more than 3 weeks
in administering the drug were all considered as
significant modifications to protocol. Of the
73 children, 52 (71%) achieved a complete
remission on initial therapy, 6 patients achieved a
good partial remission while a further five showed
only a poor partial response.
Four of the partial responders achieved a
complete remission on subsequent therapy, and of
these, 3 are alive and disease-free at intervals
ranging from 13 months to 6 years. The overall
complete response rate was therefore 77%. No
child who failed to achieve a complete response is a
long term survivor.
Ten patients failed to respond to initial therapy
and of these, 6 had metastatic disease at diagnosis
and the other 4 had evidence ofnodal spread and/or
locally invasive disease. The median duration of
survival for the non responders was 24 weeks. Only
4 of the 14 children with metastatic disease at
diagnosis achieved a complete remission and of
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Figure 8 Effect ofhistology on overall survival in childhood rhabdomyosarcoma.
these only one patient, a boy with a paratesticular
primary who had bone marrow involvement at
presentation, is currently alive with no evidence of
disease at 3 years from diagnosis.
Relapses
Although 52/73 patients achieved a complete
remission on initial therapy, 19 (37%) of these
complete responders have subsequently relapsed
and the relapse free survival is 45%. The median
time to first relapse for children achieving complete
remission on initial therapy was 14.5 months, which
is similar to the findings of other series (Heyn et
al., 1974). At relapse, 8 of the 19 children had
disease confined to the primary site, 8 developed
distant metastases with no sign of recurrent disease
at the primary site while 3 children had evidence
both of metastatic disease and of local recurrence.
Ten of these 19 relapses occurred in girls. Taking
into account the smaller number of girls in the
series (33 girls vs 40 boys) there was a slight excess
of girls amongst relapsing patients. This has also
been observed by Niefeld et al. (1979).
The median duration of survival from the time of
first relapse was 6 months, with a range of 2 weeks
to 70 months. Nine (47%) of the 19 children who
relapsed, achieved a second complete remission
with further therapy, whilst a further 2 patients are
currently on treatment following a recent relapse.
Four of the 9 children who achieved a complete
response following a first relapse have had a second
relapse, after disease free intervals ranging from 4
to 16 months. The other 5 children remain well and
disease free at intervals ranging from 6 months to
nearly 6 years. Five children have relapsed after
more than 2 years following diagnosis, and of these,
4 have been boys with paratesticular primaries. The
latest time at which a first relapse has been
observed, occurred at 3 years from diagnosis.
Discussion
Radical changes in the management of
rhabdomyosarcoma have occurred over the past
decade and greater reliance is now placed on
radiotherapy and chemotherapy to control local
disease in sites where previously radical surgery
would have been the treatment of choice. It is
generally accepted that a multi-modality approach
to the management of rhabdomyosarcoma provides
the best chance of long term survival. However, the
optimum duration and combination of therapies
remain subjects ofconsiderable debate.
The interplay of a variety of factors including
stage, size, site, sex and histological'type makes it
extremely difficult to study the effect of different
therapeutic protocols on outcome. However, there
is little doubt that the extent of disease at diagnosis
exerts the greatest influence on prognosis.
Unfortunately, any comparison of survival rates
between series from different institutions has been
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confounded by the fact that there is no universally
accepted staging system for rhabdomyosarcoma.
Due to the changing emphasis in treatment, the St.
Jude system, first described by Pratt (1969) now
seems inappropriate for many primary sites.
The CSTG has defined a clinical classification,
the Barts/Marsden staging system, which is similar
to that described by Jaffe et al. (1973). This system
incorporates some of the more important concepts
of both the St. Jude and the TNM classifications
and appears to give a good differential with regard
to outcome. In this series it has clearly shown that
the children with the best prognosis are those with
locally "confined" tumours (BM stages IA and IB)
i.e. tumours which have not spread to nodes or
distant sites and which have not infiltrated
contiguous tissues. It has also shown that complete
surgical resection of locally "confined" tumours
does not improve prognosis as we have found no
significant difference in outcome between patients
with Stage IA and IB tumours. The Barts/Marsden
system defines a subgroup of children who have
tumours extending outside the tissue of origin to
infiltrate contiguous tissue, usually bone (BM Stage
IIA). These children do badly on standard
treatment and should therefore be classified as
"poor risk" patients. The system also shows that
children with nodal involvement (BM Stage IIB)
fare badly and confirms the findings of other
classification systems that children with metastatic
disease at diagnosis (BM Stage IIIA and IIIB) have
a very poor prognosis.
The overall actuarial 5-year survival rate for
children in our series was 58%, ranging from
<15% in children with metastatic disease to 86%
in children with locally confined tumours. These
results are similar to those reported by the
Intergroup Rhabdomyosarcoma Study Group
(Maurer et al., 1977).
In our series, the orbit was the most common
primary site, and the children with tumours in this
site were found to have the best prognosis, with a
survival rate of 94% at 5 years. All but 2 of these
children had Stage IA or B disease. This may
reflect early detection of disease within the orbit.
The paucity of lymphatics within the orbit may
explain the infrequency of lymphatic spread.
During the 1960's a radical surgical approach
with exenteration was recommended for rhab-
domyosarcoma of the orbit. This present series
confirms the finding of Donaldson et al. (1973) that
biopsy followed by intensive chemotherapy and
irradiation can result in long term disease control,
thereby avoiding the necessity for exenteration, a
severely mutilating operation. Only one child has
developed serious ocular complications as a result
of radiation treatment; in this case enucleation was
unfortunately required because of severe keratitis.
One other child has required a subsequent
exenteration because of recurrent disease at the
primary site.
Rhabdomyosarcoma of the urogenital tract was
the second commonest primary site in this series.
Boys with paratesticular tumours and girls with
vaginal primaries both appeared to have a good
prognosis, whereas children with perineal, prostatic
and unspecified pelvic primaries fared much less
well. Nodal involvement was seen in 24% of
children with tumours of the urogenital tract and
lymphangiography should therefore be considered
in all patients with tumours originating in these
sites. In 1977 the committee for the Intergroup
Rhabdomyosarcoma Study reported a 19%
incidence of regional node involvement in children
with genito-urinary rhabdomyosarcoma (Lawrence
et al., 1977) and a subsequent report from the
group (Tefft et al., 1980) described positive node
involvement in 15/38 children who had undergone
regional node sampling.
It is of interest that there appears to be a trend
for girls to do less well than boys, although in this
series the difference in survival fails to reach
statistical significance. However, a similar trend
which is statistically significant has been observed
in an analysis of the national data collected by the
Childhood Cancer Research Group in Oxford.
(Stiller, 1982 personal communication). In our
series, the poorer prognosis for females appeared to
be related to the higher proportion of females with
tumours in unfavourable sites i.e. pelvic and non-
orbital head and neck sites, who had more
extensive disease at diagnosis. However, those
findings were not corroborated in the national
series, where an even distribution between the sexes
was found for these sites.
In our series, children with tumours of alveolar
histology, had a much poorer prognosis than
those with embryonal histology with survival
rates of 68% and 25% for embryonal and alveolar
histologies respectively. This finding is similar to
that observed by the Intergroup rhabdomyo-
sarcoma study who reported a mortality of 62% in
patients with alveolar histology compared to 38%
in children with embryonal histology (Hays et al.,
1982b). However, in our series the poor prognosis
of children with tumours of alveolar histology was
also related to the stage of the disease, as 87% of
the children with alveolar histology had
"'unconfined" tumours (BM stages II and III)
compared to only 33% of children with embryonal
histology. It would therefore appear that tumours
of alveolar histology have a tendency to infiltrate
locally and to metastasise to distant sites.
Although 77% of the patients eventually
achieved a complete response, it was disappointing
to find that over a third (37%) of these patients206 J.E. KINGSTON et al.
subsequently relapsed. Recurrent disease at the
primary site was present in 58% of the patients
who relapsed. The long term salvage rate following
a relapse was only 15%. The median time to first
relapse was 14.5 months, and it is chastening to
find that there are a significant number of relatively
"late" relapses, 5 out of 19 occurring more than 2
years from diagnosis, emphasising the need for long
term surveillance of these children (Maurer et al.,
1977).
The advent of CT scanning has made a
considerable contribution to the management of
rhabdomyosarcoma and embryonal sarcoma, both
in the initial assessment at diagnosis and in
subsequent evaluation and follow up. It has been of
particular value in children with primary lesions in
the pelvis and nasopharynx, where it has been able
to demonstrate the very extensive nature of many
of the tumours in these sites. A more aggressive
approach in the treatment of tumours of the
nasopharynx was introduced by the CSTG in 1977,
but as yet the number of children treated on the
more intensive protocol is too small to say whether
the intensification of therapy has made a significant
impact on prognosis. Similarly children with pelvic
primaries require aggressive therapy to achieve
control of their disease, and the results of our
recent treatment protocols for tumours in these
sites remain disappointingly poor.
In conclusion, it is encouraging that considerable
improvements in prognosis have resulted from the
introduction of a multimodality approach to the
treatment of rhabdomyosarcoma and embryonal
sarcoma. Eighty-five per cent of children with
locally "confined" tumours can now expect to
survive for 5 years and are hopefully cured of their
disease. Unfortunately, the prognosis for children
with "unconfined"'disease remains extremely poor,
and it is in these children that new therapeutic
approaches are required. Responses to high dose
chemotherapy have been seen in children with
relapsed rhabdomyosarcoma resistant to con-
ventional doses ofcytotoxic agents. Members of the
CSTG are therefore currently assessing the value of
high dose melphalan with autologous marrow
rescue, used in an adjuvant role following 6 courses
of chemotherapy at conventional dosage, for
patients defined as poor risk i.e. those with
"unconfined" or advanced stage disease.
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